Arrowhead Pharmaceuticals Inc (ARWR) financials
Arrowhead Pharmaceuticals revenue and earnings by year
Arrowhead Pharmaceuticals's revenue was $829 million in the fiscal year to September 30, 2025, up 23258.2% from the year before. Net income was -$1.63 million, -0.2% of revenue. Since the fiscal year to September 30, 2016, revenue has grown 159.0% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 829 | 4 | 241 | 243 | 138 | 88 | 169 | 16 | 31 | 0 |
| Revenue growth | 23258.2% | -98.5% | -1.0% | 75.9% | 57.2% | -47.9% | 945.7% | -48.6% | 19736.5% | — |
| Operating income | 98 | -601 | -205 | -179 | -149 | -93 | 61 | -56 | -37 | -88 |
| Operating margin | 11.9% | -16927.1% | -85.2% | -73.4% | -107.8% | -105.9% | 36.3% | -346.5% | -117.8% | -55329.7% |
| Net income | -2 | -599 | -205 | -176 | -141 | -85 | 68 | -54 | -34 | -82 |
| Net margin | -0.2% | -16882.4% | -85.3% | -72.4% | -101.9% | -96.1% | 40.3% | -337.3% | -109.5% | -51614.6% |
| Diluted EPS | -$0.01 | -$5.00 | -$1.92 | -$1.67 | -$1.36 | -$0.84 | $0.70 | -$0.66 | -$0.47 | -$1.33 |
| Free cash flow | 157 | -604 | -331 | -189 | 148 | -108 | 161 | -49 | -32 | -68 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open ARWR in Markets.
See also: ARWR returns
No forecast, no recommendation. This page describes Arrowhead Pharmaceuticals Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.